Management of glucocorticoid-induced osteoporosis. (Q38033444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Management of glucocorticoid-induced osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Adolfo Díez-Pérez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

R Rizzoli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J D Adachi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

W Dere

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J P Devogelaer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J A Kanis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Laslop

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

B Mitlak

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Papapoulos

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Ralston

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Reiter

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Werhya

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J Y Reginster

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

English

0 references

publication date

10 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

Calcified Tissue International

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

225-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22878667%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00223-012-9630-5

10 February 2020

exact match

0 references

cites work

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

In whom and how to prevent glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Use of inhaled corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Are inhaled corticosteroids associated with an increased risk of fracture in children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Effects of low-dose prednisone on bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Osteocyte: the unrecognized side of bone tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Advances in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Minireview: live and let die: molecular effects of glucocorticoids on bone cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Management of osteoporosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Children and the risk of fractures caused by oral corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

How to prevent glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Glucorticoids and bone: some general remarks and some special observations in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Matrix-embedded cells control osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Glucocorticoid dose determines osteocyte cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Cathepsin K inhibitors: a novel target for osteoporosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Glucocorticoids are not always deleterious for bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Sensitivity of bone to glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Use of oral corticosteroids in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Fracture risk with intermittent high-dose oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9630-5